Fan Jerry, Hammonds Kendall, Izekor Bright, Jones Clinton, McGrade Patrick, Michel Jeffrey B, Widmer R Jay
Division of Internal Medicine, Scott & White Heart Memorial Hospital, Baylor Scott & White Health, Temple, TX.
Division of Biostatistics, Scott & White Heart Memorial Hospital, Baylor Scott & White Health, Temple, TX.
Ochsner J. 2021 Fall;21(3):261-266. doi: 10.31486/toj.20.0135.
Cardiac troponins I and T are highly sensitive and specific markers for acute myocardial infarction (AMI). However, a wide range of non-AMI conditions can also cause significant elevations in cardiac troponins. Given the deleterious impact of misdiagnosis of AMI, the ability to risk-stratify patients who present with an elevated troponin is paramount. We hypothesized that the maximum troponin level would be more predictive of mortality and the diagnosis of AMI than the initial troponin level or change in troponin level. Patient records from a 9-hospital system (n=30,173) in Texas were reviewed during a 24-month period in 2016-2017. Data collected for patients aged ≥40 years included diagnoses, troponin I, demographic data (age, sex, smoking history, and chronic medical conditions), and death during hospitalization. We used logistic regression with the Firth penalized likelihood approach to determine the predictive ability of initial, maximum, and change in troponin level for mortality and the diagnosis of AMI. Demographic characteristics of our cohort included a median age of 70 years, with 48.05% male and 51.95% female. The most common preexisting risk factor was hypertension in 78.81% of the cohort. Notable findings from the logistic regression include the predictive ability of maximum troponin on the odds of death by 0.7% for each unit of increase in troponin value. Also, the odds of AMI increased by 3.1% for each unit of increase in the maximum troponin value. Regardless of the level, a detectable amount of troponin in the serum results in a significantly elevated risk of mortality. Many patients with elevated troponin levels leave the hospital without a specific diagnosis, which can lead to poor outcomes because a detectable troponin does not represent a no-risk population. Our study demonstrates that maximum troponin level is a more sensitive and specific predictor of mortality than initial or change in troponin. Similarly, maximum troponin is the most predictive of AMI vs other causes of troponin elevation, likely because of the correlation between rising troponin levels and cardiomyocyte damage. Further studies are needed to correlate maximum troponin levels and clinical manifestations, which may be helpful in redefining AMI so that AMI can be distinguished more easily from non-AMI diagnoses.
心肌肌钙蛋白I和T是急性心肌梗死(AMI)高度敏感和特异的标志物。然而,多种非AMI情况也可导致心肌肌钙蛋白显著升高。鉴于AMI误诊的有害影响,对肌钙蛋白升高患者进行风险分层的能力至关重要。我们假设,与初始肌钙蛋白水平或肌钙蛋白水平变化相比,最大肌钙蛋白水平对死亡率和AMI诊断的预测性更强。在2016 - 2017年的24个月期间,对得克萨斯州一个9家医院系统的患者记录(n = 30173)进行了回顾。收集的≥40岁患者的数据包括诊断、肌钙蛋白I、人口统计学数据(年龄、性别、吸烟史和慢性疾病)以及住院期间的死亡情况。我们使用带Firth惩罚似然法的逻辑回归来确定肌钙蛋白初始水平、最大水平及变化对死亡率和AMI诊断的预测能力。我们队列的人口统计学特征包括年龄中位数为70岁,男性占48.05%,女性占51.95%。最常见的既往危险因素是高血压,在队列中占78.81%。逻辑回归的显著发现包括,肌钙蛋白每升高一个单位,最大肌钙蛋白对死亡几率的预测能力增加0.7%。同样,最大肌钙蛋白每升高一个单位,AMI的几率增加3.1%。无论水平如何,血清中可检测到的肌钙蛋白量都会导致死亡率显著升高。许多肌钙蛋白水平升高的患者出院时没有明确诊断,这可能导致不良后果,因为可检测到的肌钙蛋白并不代表无风险人群。我们的研究表明,最大肌钙蛋白水平比初始肌钙蛋白水平或肌钙蛋白变化对死亡率的预测更敏感、更特异。同样,与肌钙蛋白升高的其他原因相比,最大肌钙蛋白对AMI的预测性最强,这可能是因为肌钙蛋白水平升高与心肌细胞损伤之间存在相关性。需要进一步研究将最大肌钙蛋白水平与临床表现相关联,这可能有助于重新定义AMI,以便更轻松地将AMI与非AMI诊断区分开来。